Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer
Koichi Azuma, Keiichi Ota, Akihiko Kawahara, et al.
Annals of Oncology (2014) Vol. 25, Iss. 10, pp. 1935-1940
Open Access | Times Cited: 596

Showing 1-25 of 596 citing articles:

The lung microenvironment: an important regulator of tumour growth and metastasis
Nasser K. Altorki, Geoffrey J. Markowitz, Dingcheng Gao, et al.
Nature reviews. Cancer (2018) Vol. 19, Iss. 1, pp. 9-31
Open Access | Times Cited: 908
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Kim C. Ohaegbulam, Amer Assal, Eszter Lázár‐Molnár, et al.
Trends in Molecular Medicine (2014) Vol. 21, Iss. 1, pp. 24-33
Open Access | Times Cited: 746
PD-L1 expression in human cancers and its association with clinical outcomes
Jinming Yu, Xin Wang, Feifei Teng, et al.
OncoTargets and Therapy (2016) Vol. Volume 9, pp. 5023-5039
Open Access | Times Cited: 691
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Nan Chen, Wenfeng Fang, Jianhua Zhan, et al.
Journal of Thoracic Oncology (2015) Vol. 10, Iss. 6, pp. 910-923
Open Access | Times Cited: 608
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma
Chee Khoon Lee, Johnathan Man, Sarah J. Lord, et al.
JAMA Oncology (2017) Vol. 4, Iss. 2, pp. 210-210
Open Access | Times Cited: 496
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC
Aaron Lisberg, Amy L. Cummings, Jonathan W. Goldman, et al.
Journal of Thoracic Oncology (2018) Vol. 13, Iss. 8, pp. 1138-1145
Open Access | Times Cited: 487
PD-L1 Expression in Lung Cancer
Hui Yu, Theresa A. Boyle, Caicun Zhou, et al.
Journal of Thoracic Oncology (2016) Vol. 11, Iss. 7, pp. 964-975
Open Access | Times Cited: 418
Induction of PD-L1 Expression by the EML4–ALK Oncoprotein and Downstream Signaling Pathways in Non–Small Cell Lung Cancer
Keiichi Ota, Koichi Azuma, Akihiko Kawahara, et al.
Clinical Cancer Research (2015) Vol. 21, Iss. 17, pp. 4014-4021
Open Access | Times Cited: 412
EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
Zhong‐Yi Dong, Jia‐Tao Zhang, Si‐Yang Maggie Liu, et al.
OncoImmunology (2017) Vol. 6, Iss. 11, pp. e1356145-e1356145
Open Access | Times Cited: 381
Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
Jiabei He, Ying Hu, Mingming Hu, et al.
Scientific Reports (2015) Vol. 5, Iss. 1
Open Access | Times Cited: 376
PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
Sara Gandini, Daniela Massi, Mario Mandalà
Critical Reviews in Oncology/Hematology (2016) Vol. 100, pp. 88-98
Closed Access | Times Cited: 343
Lung Cancer Staging and Prognosis
Gavitt A. Woodard, Kirk D. Jones, David M. Jablons
Cancer treatment and research (2016), pp. 47-75
Closed Access | Times Cited: 322
Immunosuppression associated with chronic inflammation in the tumor microenvironment
Dingzhi Wang, Raymond N. DuBois
Carcinogenesis (2015) Vol. 36, Iss. 10, pp. 1085-1093
Open Access | Times Cited: 307
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
Weijie Ma, Barbara M. Gilligan, Jianda Yuan, et al.
Journal of Hematology & Oncology (2016) Vol. 9, Iss. 1
Open Access | Times Cited: 301
Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway
Qian Wu, Jiang Li, Sicheng Li, et al.
Acta Pharmacologica Sinica (2020) Vol. 42, Iss. 1, pp. 1-9
Open Access | Times Cited: 300
The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
Nan Zhang, Yuanyuan Zeng, Wenwen Du, et al.
International Journal of Oncology (2016) Vol. 49, Iss. 4, pp. 1360-1368
Open Access | Times Cited: 293
Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma
Patcharee Ritprajak, Miyuki Azuma
Oral Oncology (2014) Vol. 51, Iss. 3, pp. 221-228
Open Access | Times Cited: 291
Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer
Fernando Concha‐Benavente, Raghvendra M. Srivastava, Sumita Trivedi, et al.
Cancer Research (2015) Vol. 76, Iss. 5, pp. 1031-1043
Open Access | Times Cited: 281
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
Wendy A. Cooper, Trần Nam Thắng, Ricardo E. Vilain, et al.
Lung Cancer (2015) Vol. 89, Iss. 2, pp. 181-188
Closed Access | Times Cited: 276
PD-L1
Anthousa Kythreotou, Abdul Siddique, Francesco Mauri, et al.
Journal of Clinical Pathology (2017) Vol. 71, Iss. 3, pp. 189-194
Open Access | Times Cited: 272
Refining the treatment of NSCLC according to histological and molecular subtypes
Anish Thomas, Stephen V. Liu, Deepa S. Subramaniam, et al.
Nature Reviews Clinical Oncology (2015) Vol. 12, Iss. 9, pp. 511-526
Closed Access | Times Cited: 272
Programmed death ligand 1 signals in cancer cells
Anand Kornepati, Ratna K. Vadlamudi, Tyler J. Curiel
Nature reviews. Cancer (2022) Vol. 22, Iss. 3, pp. 174-189
Open Access | Times Cited: 266
KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma
Nan Chen, Wenfeng Fang, Zhong Lin, et al.
Cancer Immunology Immunotherapy (2017) Vol. 66, Iss. 9, pp. 1175-1187
Open Access | Times Cited: 254
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
Ioannis Zerdes, Alexios Matikas, Jonas Bergh, et al.
Oncogene (2018) Vol. 37, Iss. 34, pp. 4639-4661
Open Access | Times Cited: 252
The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis
A. Wang, H.Y. Wang, Yi Liu, et al.
European Journal of Surgical Oncology (2015) Vol. 41, Iss. 4, pp. 450-456
Closed Access | Times Cited: 248
Page 1 - Next Page

Scroll to top